Indikation:	Studientitel:	Leiter klinische Prüfung:	Ansprechpartner:
AML	Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome. The Biology and Outcome (BiO)-Project.	Prof. Dr. med. Hartmut Döhner, Ulm	PD Dr. med. J. Walz, Tübingen
AML	Randomized phase III study of intensive chemotherapy with or without da-satinib (Sprycel™) in adult patients with newly diagnosed core-binding factor acute myeloid leukemia (CBF-AML). (AMLSG 21-13).	Prof. Dr. med. Hartmut Döhner, Ulm	PD Dr. med. J. Walz, Tübingen
AML	PATIENTENREKRUTIERUNG GESCHLOSSEN!! Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemia. (AMLSG 23-14).	Prof. Dr. med. R.F. Schlenk, Ulm	PD Dr. med. J. Walz, Tübingen
AML	NAPOLEON-Register der deutschen AML Intergroup. (Napoleon).	Prof. Dr. med. R.F. Schlenk, Ulm	PD Dr. med. J. Walz, Tübingen
AML	Phase I/II-Studie: Blasten-Sensibilisierung gegenüber dem Vitamin-Aderivat All-Trans-Retinsäure (ATRA) durch Tranylcypromin (TCP), einen Hemmstoff des Enzyms LSD1 (Lysin-Spezifische Demethylase 1), bei der Behandlung akuter myeloischer Leukämie (AML) / MDS. (TRANSATRA).	Prof. Dr. med. Michael Lübbert, Freiburg	Prof. Dr. med. J. Walz, Tübingen
AML	„A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLine-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute prOmyelocytic leukemia - APOLLO-TRIAL“.	Prof. Dr. med. Uwe Platzbecker, Dresden	PD Dr. med. J. Walz, Tübingen

AML	A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy.	Prof. Dr. med. Carsten Müller-Tidow, Halle (Saale)	PD Dr. med. J. Walz, Tübingen
AML	PATIENTENREKRUTIERUNG GESCHLOSSSEN!! First in man study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease – FLYSYN-Studie.	Prof. Dr. med. Helmut Salih, Tübingen	Prof. Dr. med. Helmut Salih, Tübingen